NCT01693432View on ClinicalTrials.gov

Docetaxel and S-1 for Advanced Esophageal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Esophageal Neoplasms
Interventions
DRUG

DS (docetaxel+S-1)

"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"

Trial Locations (1)

Unknown

RECRUITING

Hallym University Medical Center, Anyang

Sponsors
All Listed Sponsors
collaborator

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

lead

Hallym University Medical Center

OTHER

NCT01693432 - Docetaxel and S-1 for Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter